agenebio logo
  • About Us
    • Management
    • Board of Directors
    • Job Opportunities
  • Pipeline
    • AGB101 for MCI due to AD
    • About MCI due to Alzheimer’s Disease
    • Novel GABA(A) α5 Discovery Program
  • The Science
  • Newsroom
  • Publications
  • Investor Relations
  • Patient Resources
    • MCI due to Alzheimer’s Disease
    • Autism
    • Schizophrenia

Dr. Sharon Rosenzweig-Lipson, Vice President of Research and Development, Presents at Alzheimer’s Association International Conference

Recent Posts

  • Medical News Today: Could a once-daily pill for seizures also treat Alzheimer’s disease?
  • AgeneBio’s Phase 2B Trial Shows AGB101 Slows Progression of Brain Atrophy in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Who Are Non-Carriers of the APoE-4 Allele
  • AgeneBio Founder Michela Gallagher Presents Hope4MCI Results at 12th Alzheimer’s & Parkinson’s Drug Development Summit
  • AgeneBio leadership presents at American Society for Experimental Neurotherapeutics Annual Meeting
  • Richard Mohs, AgeneBio Vice President of Clinical Development, Presents at the 15th Annual CTAD Conference

Recent Comments

    Archives

    • October 2024
    • April 2024
    • March 2024
    • November 2022
    • December 2021
    • August 2021
    • July 2021
    • April 2021
    • February 2021
    • January 2021
    • July 2020
    • June 2020
    • December 2019
    • November 2019
    • September 2019
    • May 2019
    • January 2019
    • October 2018
    • April 2018
    • March 2018
    • February 2018
    • September 2017
    • July 2017
    • June 2017
    • December 2016
    • September 2016
    • February 2016
    • December 2015
    • November 2015
    • October 2015
    • September 2015
    • July 2015
    • April 2015
    • March 2015
    • January 2015
    • November 2014
    • July 2014
    • March 2014
    • October 2012
    • August 2012
    • May 2012
    • July 2011

    Categories

    • Events
    • In the News
    • Recent News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    agenebio therapeutic solutions for neurodegeneration

    agenebio logo

    AgeneBio, Inc.
    1340 Smith Avenue, Suite 200
    Baltimore, MD 21209

    P: 410.779.1260

    AgeneBio-Inc

    @AgeneBio

     

    • Privacy Policy
    • Terms of Use

    ©2025 AgeneBio, Inc. All rights reserved.

    Quick Links

    • About Us
      • Management
      • Board of Directors
      • Job Opportunities
    • Pipeline
      • AGB101 for MCI due to AD
      • About MCI due to Alzheimer’s Disease
      • Novel GABA(A) α5 Discovery Program
    • The Science
    • Newsroom
    • Publications
    • Investor Relations
    • Patient Resources
      • MCI due to Alzheimer’s Disease
      • Autism
      • Schizophrenia
    • Privacy Policy
    • Terms of Use

    ©2025 AgeneBio, Inc. All rights reserved.

    Top